iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Short Interest Update

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the recipient of a large drop in short interest during the month of March. As of March 13th, there was short interest totaling 45,077 shares, a drop of 36.4% from the February 26th total of 70,842 shares. Based on an average daily volume of 39,290 shares, the short-interest ratio is currently 1.1 days. Currently, 0.9% of the shares of the stock are sold short.

iShares Genomics Immunology and Healthcare ETF Price Performance

Shares of IDNA opened at $28.51 on Friday. The company has a market capitalization of $142.55 million, a P/E ratio of 14.76 and a beta of 1.07. iShares Genomics Immunology and Healthcare ETF has a one year low of $17.26 and a one year high of $31.39. The business’s 50 day simple moving average is $29.37 and its 200-day simple moving average is $26.80.

Hedge Funds Weigh In On iShares Genomics Immunology and Healthcare ETF

Several large investors have recently made changes to their positions in IDNA. Portland Global Advisors LLC bought a new stake in iShares Genomics Immunology and Healthcare ETF during the 2nd quarter worth about $2,099,000. Flow Traders U.S. LLC acquired a new stake in shares of iShares Genomics Immunology and Healthcare ETF during the 2nd quarter worth approximately $931,000. Ameriprise Financial Inc. grew its position in shares of iShares Genomics Immunology and Healthcare ETF by 8.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 71,473 shares of the company’s stock worth $1,688,000 after buying an additional 5,540 shares during the period. Finally, Triumph Capital Management bought a new stake in shares of iShares Genomics Immunology and Healthcare ETF during the 3rd quarter valued at $35,000.

About iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.